PDCD1 and cancer: Since anti‐CTLA‐4 and anti‐PD‐1 are two different immune checkpoints and the combination of both has already shown significant therapeutic effects in terms of overall survival and response rates in cancer patients,40 we also explored whether TF combined with CTLA‐4 antibody therapy has synergistic antitumor effects.